MicroRNA expression profiles predict clinical phenotypes and prognosis in chromophobe renal cell carcinoma

Ge, Yu‐Zheng; Hui, Xin; Lu, Tian-Ze; Xu, Zheng; Peng, Yu; Zhao, Yu; Li, Minghao; Zhao, Yan; Zhong, Bing; Xu, Xiao; Zhou, Lin; Wu, Rongqian; Xu, Luwei; Wu, Jianping; Li, Wencheng; Zhu, Jun; Jia, Ru

doi:10.1038/srep10328

Cited by 36 publications

(28 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miR-21-5p acts as a broad-spectrum biomarker for many other solid cancers, including gastric, pancreatic, breast, and prostate cancers [11, 46–48]. One advantage characteristic for the serum miR-21-5p level is its relatively higher sensitivity and specificity in diagnosis of CRC than both NCs and other cancer patients [49, 50]. miR-425-5p has been identified as a potential biomarker in renal cell carcinoma, lung squamous cell carcinoma, breast cancer and bladder cancer [30, 51, 52].…”

Section: Discussionmentioning

confidence: 99%

A panel of microRNA signature in serum for colorectal cancer diagnosis

et al. 2017

View full text Add to dashboard Cite

Dysregulated expression of specific microRNAs (miRNAs) in serum has been recognised as promising diagnostic biomarkers for colorectal cancer (CRC). In the initial screening phase, a total of 32 differentially expressed miRNAs were selected by quantitative reverse transcription polymerase chain reaction (qRT-PCR) based Exiqon panel with 3 CRC pool samples and 1 normal control (NC) pool. Using qRT-PCR, selected serum miRNAs were further confirmed in training (30 CRC VS. 30 NCs) and testing stages (136 CRC VS. 90 NCs). We identified that serum levels of miR-19a-3p, miR-21-5p and miR-425-5p were significantly higher in patients with CRC than in NCs. The areas under the receiver operating characteristic (ROC) curve of the three-miRNA panel were 0.86, 0.74 and 0.87 for the training, testing and the external validation stages (30 CRC VS. 18 NCs), respectively. Significantly, elevated expression of the three miRNAs was also observed in CRC tissues (n = 24). Furthermore, the expression levels of the three miRNAs were significantly elevated in exosomes from CRC serum samples (n = 10). In conclusion, we identified a serum three-miRNA panel for the diagnosis of CRC.

show abstract

Section: Discussionmentioning

confidence: 99%

A panel of microRNA signature in serum for colorectal cancer diagnosis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Among these 2 miRNAs, miR-NA-425 has been associated with tumor stage in gastric (32) and lung cancer (33), and in RCC, it has been suggested as being a potential ccRCC biomarker (34) associated with poor prognosis for chromophobe RCC (35) and decreased PFS during sunitinib treatment (17). miR-1307 plays a role in chemoresistance in ovarian cancer (36), and it has been suggested to contribute to colorectal carcinogenesis (37).…”

Section: Discussionmentioning

confidence: 99%

Deep sequencing reveals microRNAs predictive of antiangiogenic drug response

García-Donás¹,

Beuselinck²,

Inglada-Pérez³

et al. 2016

JCI Insight

View full text Add to dashboard Cite

“…We excluded non-qualified miRNas from the data according to the following criteria: (1) the expression was less than 1 RPM in at least 90% of the samples; (2) the expression had less than 1.5 folds changes from the median value in at least 80% of the samples. Then, RNaseq expression data log2 transformed were conducted to standardize the expression values of each filtered miRNa [20].…”

Section: Methodsmentioning

confidence: 99%

A microRNA expression signature as a predictor of survival for colon adenocarcinoma

Xu¹,

Kuang²,

Wang³

et al. 2017

neo

View full text Add to dashboard Cite

Colon cancer is a major cause of cancer mortality worldwide and most colon cancers are adenocarcinoma. MicroRNA (miRNA) expression signature has been shown to be able to predict progression and prognosis of various cancers. The aim of our study was to explore a novel signature of microRNA expression for predicting survival of colon adenocarcinoma patients. By analyzing the miRNA expression profiles and clinical information of 329 colon adenocarcinoma patients derived from The Cancer Genome Atlas database. 129 miRNAs were identified to be expressed differentially between the cancer and adjacent tissues. Among them, 27 miRNAs were found to be associated with the corresponding clinical characteristics of the patients. Furthermore, 7 miRNAs (let-7a-2, mir-32, mir-181a-1, mir-197, mir-328, mir-505 and mir-652) were found to be significantly correlated with the patient survival. The risk established by the 7-miRNA signature we built was proved be an independent prognostic factor (Hazard ratio [HR] = 2.048; 95% CI = 1.144-3.664; p, 0.016). In summary, our study identified miRNAs correlated with progression and prognosis of colon adenocarcinoma and built a 7-microRNA expression signature for prediction of the survival of the patients with colon adenocarcinoma.

show abstract

MicroRNA expression profiles predict clinical phenotypes and prognosis in chromophobe renal cell carcinoma

Cited by 36 publications

References 40 publications

A panel of microRNA signature in serum for colorectal cancer diagnosis

A panel of microRNA signature in serum for colorectal cancer diagnosis

Deep sequencing reveals microRNAs predictive of antiangiogenic drug response

A microRNA expression signature as a predictor of survival for colon adenocarcinoma

Contact Info

Product

Resources

About